Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
RESEARCH TOOLSreports
AVDL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.39 - $19.09
Previous CloseN/A
Volume358.54K
Average Volume (3M)1.67M
Market Cap
$822.93M
Enterprise Value$1.23B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 13, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding96,361,530
10 Day Avg. Volume1,350,032
30 Day Avg. Volume1,672,517
Standard Deviation0.24
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.87
Price to Cash Flow (P/CF)-29.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit45.49
Enterprise Value/Ebitda-20.39
Forecast
1Y Price Target
$17.11Price Target Upside102.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Legal ProceedingsThe three-judge panel appeared receptive to Avadel’s argument that it can seek FDA approval under the safe harbor provision.
Market PotentialThe potential for Lumryz in idiopathic hypersomnia, an indication with an existing oxybate approval, remains a key upside opportunity for the stock.
Sales GrowthPatient starts continue to outpace estimates, indicating potential growth in the oxybate market.
Bears Say
Financial ConstraintsAvadel's ongoing cash burn and limited cash reserves suggest financial constraints.
Patient DiscontinuationDiscontinuation rates are higher among new to narcolepsy population, driven by adverse events such as nausea, vomiting, and dizziness.
Sales ForecastGuided 2025 $240-260M LUMRYZ sales were 13-15% below our/Street $293/289M, which is driven by different patient mix than expected.
---
Ownership Overview
11.27% Insiders
11.26% Mutual Funds
37.55% Other Institutional Investors
31.49% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $7.39 and its highest was $19.09 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Avadel Pharmaceuticals’s market cap is $822.93M.
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Mar 13, 2025 which is in 19 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.052.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is -0.04.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 96,361,530 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -19.325%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Currently, no hedge funds are holding shares in AVDL
---
Avadel Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.11 (102.01% Upside)
$17.11 (102.01% Upside)
Blogger Sentiment
Bullish
AVDL Sentiment 66%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $761.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.13%
12-Months-Change
Fundamentals
Return on Equity
-78.54%
Trailing 12-Months
Asset Growth
-22.08%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.
---
AVDL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress and achievements, such as strong patient growth, new FDA approvals, and positive legal outcomes. However, challenges persist with patient persistency and ongoing litigation. The sentiment is overall positive, driven by consistent growth and strategic achievements, despite the noted challenges.Read More>---
AVDL Stock 12 Month Forecast
Average Price Target
$17.11
▲(102.01% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Neurocrine
―
Supernus Pharmaceuticals
―
Heron Therapeutics
―
Xenon
―
Best Analysts Covering AVDL
1 Year
1 Year Success Rate
16/26 ratings generated profit
1 Year Average Return
+55.98%
reiterated a buy rating last month
Copying Ami Fadia's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +55.98% per trade.
---